Bruker: Attractive Valuation Ahead Of An Earnings Inflection (NASDAQ:BRKR)

Bruker ( BRKR ) is positioned for good growth as the company enters FY26. The company should benefit from a healthy backlog, easier Y/Y comparisons, and recovery in key markets, including academic and government, biopharma, and China. In addition, around $40I have over 15 years of experience investing and have provided research services to mid-sized hedge funds with assets under management between $100 and $500 million. I also have had a brief stint as a sell-side analyst. I am now focusing primarily on man ...